ALK and hepatocellular carcinoma: In 2022, tremelimumab combined with durvalumab was approved for the first time in the treatment of unresectable hepatocellular carcinoma (HCC) patients, while tremelimumab combined with durvalumab and platinum‐based chemotherapy was approved for the treatment of mNSCLC in adult patients without EGFR sensitizing mutations or anaplastic lymphoma kinase (ALK) fusion [25].